These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 12473219)
1. Targeting malignant B cells of lymphoma and leukemia with genetically engineered T-cell clones. Jensen MC Cytotherapy; 2002; 4(5):443-4. PubMed ID: 12473219 [No Abstract] [Full Text] [Related]
2. How immunology is reshaping clinical disciplines: the example of haematology. Caligaris-Cappio F Lancet; 2001 Jul; 358(9275):49-55. PubMed ID: 11454399 [TBL] [Abstract][Full Text] [Related]
3. Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy. Verhoeven D; Stoppelenburg AJ; Meyer-Wentrup F; Boes M Clin Immunol; 2018 May; 190():22-31. PubMed ID: 29499421 [TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T lymphocytes for leukemia and lymphoma. Bollard CM; Barrett AJ Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):565-9. PubMed ID: 25696912 [TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Nadler LM; Ritz J; Griffin JD; Todd RF; Reinherz EL; Schlossman SF Prog Hematol; 1981; 12():187-225. PubMed ID: 7041173 [No Abstract] [Full Text] [Related]
6. [Analysis and classification of leukemia and malignant lymphoma cells using monoclonal antibodies]. Uede T; Kikuchi K Nihon Rinsho; 1983; 41(4):815-20. PubMed ID: 6350650 [No Abstract] [Full Text] [Related]
7. Dendritic cells, T-cells and their possible role in the treatment of leukaemia and lymphoma. Davison GM Transfus Apher Sci; 2010 Apr; 42(2):189-92. PubMed ID: 20122870 [TBL] [Abstract][Full Text] [Related]
8. Genetic engineering of T cells in leukemia and lymphoma. Kochenderfer JN Clin Adv Hematol Oncol; 2014 Mar; 12(3):190-2. PubMed ID: 24927269 [No Abstract] [Full Text] [Related]
9. B & T markers in leukemia and lymphoma. Bloomfield CD Minn Med; 1979 Jul; 62(7):499-501. PubMed ID: 315029 [No Abstract] [Full Text] [Related]
10. CAR T cell therapy: inroads to response and resistance. Brown CE; Mackall CL Nat Rev Immunol; 2019 Feb; 19(2):73-74. PubMed ID: 30631206 [No Abstract] [Full Text] [Related]
11. Non T lymphoid cells can express T cell surface characteristics: normal, HCL, and a range of leukemic B cells express T cell antigens after appropriate in vitro stimulation. Worman CP; Mills KH; Cawley JC Semin Oncol; 1984 Dec; 11(4):401-4. PubMed ID: 6334367 [No Abstract] [Full Text] [Related]
12. New approaches to the treatment of non-Hodgkin's lymphoma. Frei E; Schlossman S; Israel M Cancer Treat Rep; 1977 Sep; 61(6):1209-17. PubMed ID: 332355 [No Abstract] [Full Text] [Related]
13. T-cell therapy extends cancer survival to years. Ledford H Nature; 2014 Dec; 516(7530):156. PubMed ID: 25503214 [No Abstract] [Full Text] [Related]
14. [Functional properties of T and L-lymphocytes in malignant tumors]. Shiriĭ AV Vopr Onkol; 1976; 22(10):89-99. PubMed ID: 797120 [No Abstract] [Full Text] [Related]
15. Proceedings: B and T cell membrane markers in human leukaemias and lymphomata. Seligmann M; Brouet JC; Preud'Homme JL Br J Cancer; 1975 Aug; 32(2):279-80. PubMed ID: 1082342 [No Abstract] [Full Text] [Related]
16. Monoclonal antibodies in leukaemia and lymphoma. Lancet; 1982 May; 1(8280):1055-6. PubMed ID: 6122858 [No Abstract] [Full Text] [Related]
17. Anti-idiotype antibodies reveal the existence of somatic mutation in human B cell lymphoma. Levy R; Levy S; Brown SL; Kon S; Carroll W Monogr Allergy; 1987; 22():194-203. PubMed ID: 3325832 [No Abstract] [Full Text] [Related]
20. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Epstein AL; Marder RJ; Winter JN; Stathopoulos E; Chen FM; Parker JW; Taylor CR Cancer Res; 1987 Feb; 47(3):830-40. PubMed ID: 3542194 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]